

# Financial overview

## Net revenue, SEK M

# 616

BioArctic's net revenue increased 170 percent during 2023. The revenue consisted primarily of milestone payments of SEK 592.0 M (161.5). Royalty income from sale of the drug lecanemab amounted to SEK 10.2 M (-).

## Operating profit, SEK M

# 253

Operating profit improved considerably during 2023 from a reported loss during 2022. The improved result was primarily due to the regulatory successes for lecanemab resulting in a number of significant milestone payments from Eisai.

## Cash and cash equivalents and current investments, SEK M

# 1,112

BioArctic's cash and cash equivalents and current investments increased by SEK 307 M year-on-year. The company's strong financial position facilitates robust efforts to advance the company's broad project portfolio. The objective is to help more patients, their families and society as a whole to provide treatments for disorders of the central nervous system and to create shareholder value.

	2023	2022
Net revenue, SEK M	616.0	228.3
Operating profit/loss, SEK M	252.6	-17.3
Operating margin, %	41.0	neg
Profit/loss for the year, SEK M	229.2	-11.2
Earnings per share before dilution, SEK	2.60	-0.13
Earnings per share after dilution, SEK	2.59	-0.13
Equity per share, SEK	11.85	8.92
Cash flow from operating activities, SEK M	299.0	-31.6
Cash flow from operating activities per share, SEK	3.39	-0.36
Cash, cash equivalents and short term investments, SEK M	1,111.6	805.4
Equity/asset ratio, %	88.2	91.6
Return on equity, %	25.0	-1.4
Share price at end of period, SEK	267.80	272.00

## Vision

A world in which we successfully stop the onset of neurodegenerative diseases

## Mission

Together, we create, develop, and provide drugs of the future for patients with severe neurodegenerative diseases and other conditions with significant medical needs

## Business concept

- Through pioneering research, BioArctic creates and develops biological drugs for patients with neurodegenerative diseases
- BioArctic shall generate revenue and increase the value of the company by out-licensing or commercializing proprietary drugs